Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Global E Online Ltd (GLBE) vs Eli Lilly And Co (LLY) Price & Performance

Global E Online LtdTrade
Eli Lilly And CoTrade

Price performance (Past 24H)

Key statistics

Global E Online Ltd vs Eli Lilly And Co — how do they compare? Global E Online Ltd trades at $38.45 (market cap $6.55B), while Eli Lilly And Co trades at $1,176.52 (market cap $1.03T). The key difference: Eli Lilly And Co is far larger — about 157.3× Global E Online Ltd's market cap, and Eli Lilly And Co pays a 0.6% dividend while Global E Online Ltd pays none. Which is the better fit depends on your goals.

GLBELLY
Market Cap
$6.55B$1.03T
Sector
TechnologyHealth
52-Week High
$41.59$1.24K
52-Week Low
$27.54$625.65
Enterprise Value
$6.02B$1.07T
Dividend Yield
0.6%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Global E Online Ltd

GLBE trades at $38.70, down 0.13% on the day, with a strong bullish technical signal from moving averages. The company reported Q1 2026 revenue growth of 33% year-over-year and raised full-year 2026 guidance, while maintaining a high P/E ratio of 58.18. Recent acquisition of Passport aims to enhance logistics capabilities, supporting future growth in cross-border e-commerce.

Outlook remains positive with 100% analyst buy ratings and a consensus price target of $38.00, though high valuation and recent insider sales present risks. Earnings momentum and strategic expansions provide upside potential, but investors should monitor competitive pressures and execution of growth initiatives.

Eli Lilly And Co

Eli Lilly (LLY) trades at $1,176.75, up 1.95% on the day, with strong fundamentals including a 31.66% net margin and consistent earnings beats. The stock shows a bearish technical signal near resistance at $1,177, while recent news highlights the $2.8 billion acquisition of AtaiBeckley to expand its mental health pipeline. Operating cash flow surged to $16.81 billion in 2025, supporting growth initiatives in obesity and Alzheimer's treatments.

Outlook remains positive with a $1.38K analyst price target and 73% buy ratings, but risks include competitive pressure in obesity drugs and high valuation multiples. Revenue growth of 65% in 2025 underscores momentum, though debt levels and acquisition integration pose challenges for sustained outperformance.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Global E Online Ltd

Global-e provides a platform for cross-border e-commerce, helping retailers increase international sales by localizing the shopping experience for consumers in over 200 destinations worldwide.

Read more on GLBE

About Eli Lilly And Co

Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer

Read more on LLY